Clay B. Siegall, Ph.D. has been appointed to the Board of Directors of Mirna Therapeutics. This is a biotechnology firm that is primarily focused on developing and commercializing microRNA (miRNA) therapeutics.
Clay B. Siegall, Ph.D., is the co-founder and President of Seattle Genetics. He is also its Chief Executive Officer as well as the Chairman of its Board of Directors.
Dr. Siegall has wide experience in the pharmaceutical industry. He has many achievements in building a highly successful oncology firm. All this will be used by the Mirna team to advance in its development of a number of microRNA-based therapeutics.
Clay B. Siegall believes that microRNA-based therapeutics is a new and exciting area in cancer research. He feels that Mirna is well-positioned as it has a strong pipeline that includes a number of product candidates. He is looking forward to working with this team in order to advance its programs for patients who need them.
Dr. Clay Siegall is the co-founder of Seattle Genetics. Under his leadership, a diverse pipeline of therapies based on antibodies had been developed by the company. These will help to address the medical needs of cancer patients.
The first commercial product of the company was ADCETRIS® (brentuximaesid vedotin). This got approved in 2011. The company already has a pipeline of many other such products. Besides, Seattle Genetics has entered into a number of strategic collaborations. These are the leading biotechnology as well as pharmaceutical companies in the field of oncology.
Clay B. Siegall is also guiding the capital raising activities of Seattle Genetics. They have managed to secure over $675 million. This has been through public as well as private financings. He also directed the initial public offering of the company in 2001. Clay B. Siegall serves on the Board of Directors of Alder BioPharmaceuticals too. This is a private biotechnology company.
Earlier Dr. Clay B. Siegall served with the Bristol-Myers Squibb Pharmaceutical Research Institute as well as with the National Cancer Institute, National Institutes of Health.
He has written over 70 publications. He holds 15 patents. He has a Ph.D. in Genetics. He has earned it from the George Washington University. He holds a B.S. degree in Zoology. This is from the University of Maryland.